Cagrilintide | GLP-1 (SG)
Amylin Analog + GLP-1 Receptor Agonist Blend
Blend Components:
Cagrilintide
CAS: 1415456-99-3
Formula: C194H312N54O59S2
M.W.: 4425.1146 g/mol
GLP-1 (SG)
CAS: 910463-68-2
Formula: C187H291N45O59
M.W.: 4113.5751 g/mol
Purity: 99%+ HPLC Verified
Ref No.:CGL-0002VI
Ref No.:CGL-0005VI
For Research Use Only (RUO)
Not for human or veterinary use.
Cagrilintide | GLP-1 (SG) (Blend)
Category
GLP / Metabolic Research
Form Factor
Lyophilized Powder
Blend Components
Cagrilintide
2.5 mg
5 mg
CAS: 1415456-99-3
GLP-1 (SG)
2.5 mg
5 mg
CAS: 910463-68-2
Cagrilintide
CAS
1415456-99-3
Formula
C194H312N54O59S2
Molar Mass
4425.1146 g/mol
GLP-1 (SG)
CAS
910463-68-2
Formula
C187H291N45O59
Molar Mass
4113.5751 g/mol
In stock, ready to ship
Ships same day before 12pm PST
Products are shipped in lyophilized powder form.
This dual-agonist blend combines Cagrilintide (long-acting amylin analog) with GLP-1 (SG) (GLP-1 receptor agonist) for synergistic metabolic research. Preclinical data from the CagriSema program demonstrate pronounced additive metabolic endpoint changes when both pathways are activated simultaneously, exceeding either agent alone in study models.
Description
This dual-agonist blend combines Cagrilintide (long-acting amylin analog) with GLP-1 (SG) (GLP-1 receptor agonist) for synergistic metabolic research. Preclinical data from the CagriSema program demonstrate pronounced additive metabolic endpoint changes when both pathways are activated simultaneously, exceeding either agent alone in study models.Chemical Information
Purity
99%+ HPLC Verified
Form Factor
Lyophilized Powder
Synonyms
Blend Components
Cagrilintide
2.5 mg
5 mg
CAS: 1415456-99-3
GLP-1 (SG)
2.5 mg
5 mg
CAS: 910463-68-2
Cagrilintide
CAS
1415456-99-3
Formula
C194H312N54O59S2
Molar Mass
4425.1146 g/mol
GLP-1 (SG)
CAS
910463-68-2
Formula
C187H291N45O59
Molar Mass
4113.5751 g/mol
Research Applications
- Metabolic Research: The Cagrilintide and GLP-1 (SG) blend represents a dual-agonist approach combining amylin and GLP-1 receptor activation. Study data from the CagriSema program demonstrates unprecedented adipose tissue endpoint changes exceeding 25% when both pathways are activated simultaneously.
- Endocrinology Research: This combination is studied for its effects on the incretin-amylin hormonal axis and pancreatic beta-cell function. Research investigates how simultaneous amylin analog and GLP-1 receptor agonist administration modulates postprandial glucose excursions and insulin secretion dynamics.
- Pharmaceutical Sciences: The Cagrilintide and GLP-1 (SG) combination is studied as a model for multi-target peptide therapeutics. Research focuses on pharmacokinetic interactions, optimal dosing ratios, and formulation science of co-lyophilized peptide blends.
- Neuroscience of Food Intake Research: This dual-agonist blend is investigated for its effects on central food intake regulation circuits. Research examines how combined amylin and GLP-1 receptor activation in the area postrema and hypothalamic feeding centers produces enhanced satiety signaling.
Storage Conditions
Unreconstituted
Store at -20°C to 4°C (freezer or refrigerator). Stable for 24+ months.
Reconstituted
Refrigerate at 2–8°C. Use within 30 days for optimal stability.
Avoid
Repeated freeze-thaw cycles, direct sunlight, and temperatures above 25°C.
Safety & Compliance
- Wear nitrile gloves and safety goggles when handling research compounds.
- Work in a clean, controlled environment (laminar flow hood recommended).
- Dispose of sharps and used materials in approved biohazard containers.
- This product is for laboratory research use only (RUO) — not for human or veterinary use.
Quality Assurance Standards
Each production lot is subjected to rigorous analytical evaluation to meet pharmaceutical-grade specifications. Full testing results and procedural documentation are furnished through the accompanying Certificate of Analysis (COA) with every shipment.
Certificate of Analysis
Latest COA for Cagrilintide | GLP-1 (SG) (Blend) — independently tested via HPLC and Mass Spectrometry.
Testing Methodology
Every batch undergoes a multi-stage analytical pipeline before release. Results are compiled into the Certificate of Analysis (COA) included with each order.
- • HPLC — High-Performance Liquid Chromatography confirms peptide purity ≥98%.
- • Mass Spectrometry — Validates molecular identity and correct sequence.
- • Endotoxin (LAL) — Limulus Amebocyte Lysate assay ensures endotoxin levels are within safe limits.
- • Sterility — Microbial contamination testing per USP standards.
Learn More About Peptides
Explore our research library covering purity, synthesis, storage, solubility, and more.
Research Database
Browse peer-reviewed studies, clinical trials, and scientific sources behind our peptide resources.
You May Also Like
-
$109.99
BPC-157 (Spray)
Regenerative ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$109.99
PT-141 (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$124.99
Selank (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$124.99
Semax (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details
Popular Product
Popular Product
Popular Product
Popular Product
Description
This dual-agonist blend combines Cagrilintide (long-acting amylin analog) with GLP-1 (SG) (GLP-1 receptor agonist) for synergistic metabolic research. Preclinical data from the CagriSema program demonstrate pronounced additive metabolic endpoint changes when both pathways are activated simultaneously, exceeding either agent alone in study models.Chemical Information
Purity
99%+ HPLC Verified
Form Factor
Lyophilized Powder
Synonyms
Blend Components
Cagrilintide
2.5 mg
5 mg
CAS: 1415456-99-3
GLP-1 (SG)
2.5 mg
5 mg
CAS: 910463-68-2
Cagrilintide
CAS
1415456-99-3
Formula
C194H312N54O59S2
Molar Mass
4425.1146 g/mol
GLP-1 (SG)
CAS
910463-68-2
Formula
C187H291N45O59
Molar Mass
4113.5751 g/mol
Research Applications
- Metabolic Research: The Cagrilintide and GLP-1 (SG) blend represents a dual-agonist approach combining amylin and GLP-1 receptor activation. Study data from the CagriSema program demonstrates unprecedented adipose tissue endpoint changes exceeding 25% when both pathways are activated simultaneously.
- Endocrinology Research: This combination is studied for its effects on the incretin-amylin hormonal axis and pancreatic beta-cell function. Research investigates how simultaneous amylin analog and GLP-1 receptor agonist administration modulates postprandial glucose excursions and insulin secretion dynamics.
- Pharmaceutical Sciences: The Cagrilintide and GLP-1 (SG) combination is studied as a model for multi-target peptide therapeutics. Research focuses on pharmacokinetic interactions, optimal dosing ratios, and formulation science of co-lyophilized peptide blends.
- Neuroscience of Food Intake Research: This dual-agonist blend is investigated for its effects on central food intake regulation circuits. Research examines how combined amylin and GLP-1 receptor activation in the area postrema and hypothalamic feeding centers produces enhanced satiety signaling.
Storage Conditions
Unreconstituted
Store at -20°C to 4°C (freezer or refrigerator). Stable for 24+ months.
Reconstituted
Refrigerate at 2–8°C. Use within 30 days for optimal stability.
Avoid
Repeated freeze-thaw cycles, direct sunlight, and temperatures above 25°C.
Safety & Compliance
- Wear nitrile gloves and safety goggles when handling research compounds.
- Work in a clean, controlled environment (laminar flow hood recommended).
- Dispose of sharps and used materials in approved biohazard containers.
- This product is for laboratory research use only (RUO) — not for human or veterinary use.
Quality Assurance Standards
Each production lot is subjected to rigorous analytical evaluation to meet pharmaceutical-grade specifications. Full testing results and procedural documentation are furnished through the accompanying Certificate of Analysis (COA) with every shipment.
Certificate of Analysis
Latest COA for Cagrilintide | GLP-1 (SG) (Blend) — independently tested via HPLC and Mass Spectrometry.
Testing Methodology
Every batch undergoes a multi-stage analytical pipeline before release. Results are compiled into the Certificate of Analysis (COA) included with each order.
- • HPLC — High-Performance Liquid Chromatography confirms peptide purity ≥98%.
- • Mass Spectrometry — Validates molecular identity and correct sequence.
- • Endotoxin (LAL) — Limulus Amebocyte Lysate assay ensures endotoxin levels are within safe limits.
- • Sterility — Microbial contamination testing per USP standards.
Learn More About Peptides
Explore our research library covering purity, synthesis, storage, solubility, and more.
Research Database
Browse peer-reviewed studies, clinical trials, and scientific sources behind our peptide resources.
